ETFs with exposure to Chemed Corp. : November 14, 2017 Tue, 14 Nov 2017 19:05:46 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Chemed Corp. Here are 5 ETFs with the largest exposure to CHE-US. Comparing the performance and risk of Chemed Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
See what the IHS Markit Score report has to say about Chemed Corp. Mon, 13 Nov 2017 13:06:28 +0000 The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Consumer Services sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
Chemed Corporation Declares Quarterly Dividend of 28 Cents Fri, 03 Nov 2017 15:51:00 +0000 Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 28-cents per share on the Company’s capital stock, payable on December 4, 2017, to shareholders of record as of November 13, 2017.
Chemed Corp. :CHE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 Wed, 01 Nov 2017 13:29:57 +0000 Categories: Yahoo FinanceGet free summary analysis Chemed Corp. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 417.44 million, Net Earnings of USD 35.44 million. Gross margins widened from 26.04% to 28.88% compared to the same period last year, operating (EBITDA) margins now 15.62% from 13.71%. Change in operating cash ... Read more
(Read more...)
One of Cincinnati's largest public companies agrees to $75M settlement with feds Tue, 31 Oct 2017 16:55:11 +0000 Chemed Corp. has agreed to pay $75.5 million to resolve a government lawsuit alleging that the company submitted false claims to Medicare for hospice services. “We’ve elected to settle the civil litigation without any admission of wrongdoing to avoid the cost and uncertainty of protracted litigation,” Vitas Healthcare CEO Nick Westfall said. Chemed also agreed to pay interest, certain attorney fees and expenses of whistleblowers in the case.
Chemed Settles DOJ Litigation Tue, 31 Oct 2017 15:23:00 +0000 Chemed Corporation , the parent company of VITAS Healthcare Corporation , announced today that they have reached final agreement to end the civil litigation and False Claims Act brought by the U.S.
Chemed to pay $75 mln over false claims lawsuit -Justice Dept Mon, 30 Oct 2017 21:49:25 +0000 Chemed Corp and subsidiaries including Vitas Hospice Services LLC and Vitas Healthcare Corp have agreed to pay $75 million to resolve a federal lawsuit alleging false claims for hospice services to Medicare, ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.